Trouble is, Nexavar is forcing many to take a hard look at the future of PI-88. Nexavar is already approved for liver cancer, and will already have a stranglehold on each and every one of PI-88's prospective markets by the time (and if) PI-88 gets the FDA nod.
One look at ONXX's share price in comparison to PGLA gives significant insight into the way the experts think this is going to play out. PI-88 has lost the first-mover advantage, and its potential market share has dwindled dramatically. Add the recent news that Nexavar is potent over multiple conditions (recall that PI-88 failed its trial for lung cancer), and we see the clear emergence of a blockbuster drug which will relegate PI-88 to specialty status (best-case scenario), or dismiss it altogether (a likely scenario given PI-88's inferior efficacy).
Quite honestly, it's looking more and more like PI-88 will be dead on arrival. Such is the nature of the speculative biotech landscape.
PGL Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held
